Search Results - "Wilkinson, Bethanie"

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine by Keech, Cheryl, Albert, Gary, Cho, Iksung, Robertson, Andreana, Reed, Patricia, Neal, Susan, Plested, Joyce S, Zhu, Mingzhu, Cloney-Clark, Shane, Zhou, Haixia, Smith, Gale, Patel, Nita, Frieman, Matthew B, Haupt, Robert E, Logue, James, McGrath, Marisa, Weston, Stuart, Piedra, Pedro A, Desai, Chinar, Callahan, Kathleen, Lewis, Maggie, Price-Abbott, Patricia, Formica, Neil, Shinde, Vivek, Fries, Louis, Lickliter, Jason D, Griffin, Paul, Wilkinson, Bethanie, Glenn, Gregory M

“…A recombinant SARS-CoV-2 spike protein nanoparticle vaccine delivered in the deltoid muscle on days 0 and 21 was found to be immunogenic at both 5 μg and 25 μg…”
Get full text

Tofacitinib versus Methotrexate in Rheumatoid Arthritis by Lee, Eun Bong, Fleischmann, Roy, Hall, Stephen, Wilkinson, Bethanie, Bradley, John D, Gruben, David, Koncz, Tamas, Krishnaswami, Sriram, Wallenstein, Gene V, Zang, Chuanbo, Zwillich, Samuel H, van Vollenhoven, Ronald F

“…In patients with rheumatoid arthritis, tofacitinib was associated with greater reductions in signs and symptoms than methotrexate. Herpes zoster infections and…”
Get full text

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis by van Vollenhoven, Ronald F, Fleischmann, Roy, Cohen, Stanley, Lee, Eun Bong, García Meijide, Juan A, Wagner, Sylke, Forejtova, Sarka, Zwillich, Samuel H, Gruben, David, Koncz, Tamas, Wallenstein, Gene V, Krishnaswami, Sriram, Bradley, John D, Wilkinson, Bethanie

“…In this trial of patients with rheumatoid arthritis who were on stable doses of methotrexate, tofacitinib, a novel oral Janus kinase inhibitor, was more…”
Get full text

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs by Fleischmann, Roy, Cutolo, Maurizio, Genovese, Mark C., Lee, Eun Bong, Kanik, Keith S., Sadis, Seth, Connell, Carol A., Gruben, David, Krishnaswami, Sriram, Wallenstein, Gene, Wilkinson, Bethanie E., Zwillich, Samuel H.

“…Objective To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP‐690,550) or adalimumab monotherapy with placebo for the…”
Get full text

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis by Winthrop, Kevin L, Silverfield, Joel, Racewicz, Arthur, Neal, Jeffrey, Lee, Eun Bong, Hrycaj, Pawel, Gomez-Reino, Juan, Soma, Koshika, Mebus, Charles, Wilkinson, Bethanie, Hodge, Jennifer, Fan, Haiyun, Wang, Tao, Bingham, 3rd, Clifton O

“…To evaluate tofacitinib's effect upon pneumococcal and influenza vaccine immunogenicity. We conducted two studies in patients with rheumatoid arthritis using…”
Get more information

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone by Kremer, Joel M., Cohen, Stanley, Wilkinson, Bethanie E., Connell, Carol A., French, Jonathan L., Gomez-Reino, Juan, Gruben, David, Kanik, Keith S., Krishnaswami, Sriram, Pascual-Ramos, Virginia, Wallenstein, Gene, Zwillich, Samuel H.

“…Objective To compare the efficacy, safety, and tolerability of 6 dosages of oral tofacitinib (CP‐690,550) with placebo for the treatment of active rheumatoid…”
Get full text

Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis by Conaghan, Philip G, Østergaard, Mikkel, Troum, Orrin, Bowes, Michael A, Guillard, Gwenael, Wilkinson, Bethanie, Xie, Zhiyong, Andrews, John, Stein, Amy, Chapman, Douglass, Koenig, Andrew

“…The objective of this study was to evaluate early changes in magnetic resonance imaging (MRI) and clinical disease activity measures as predictors of later…”
Get full text

Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis by Boy, Mary G., Wang, Cunshan, Wilkinson, Bethanie E., Chow, Vincent Fung-Sing, Clucas, Alan T., Krueger, James G., Gaweco, Anderson S., Zwillich, Samuel H., Changelian, Paul S., Chan, Gary

Get full text

Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials by Landewé, Robert B M, Connell, Carol A, Bradley, John D, Wilkinson, Bethanie, Gruben, David, Strengholt, Sander, van der Heijde, Désirée

“…The detection of statistically significant reductions in radiographic progression during clinical studies in patients with rheumatoid arthritis (RA) has become…”
Get full text

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans by Treanor, John J., Wilkinson, Bethanie E., Masseoud, Feda, Hu-Primmer, Jean, Battaglia, Rosalyn, O'Brien, Diane, Wolff, Mark, Rabinovich, Gina, Blackwelder, William, Katz, Jacqueline M.

“…Recent outbreaks of avian influenza in humans have demonstrated the need for vaccines for influenza viruses with pandemic potential. Recombinant hemagglutinins…”
Get full text

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial by Mallory, Raburn M, Formica, Neil, Pfeiffer, Susan, Wilkinson, Bethanie, Marcheschi, Alex, Albert, Gary, McFall, Heather, Robinson, Michelle, Plested, Joyce S, Zhu, Mingzhu, Cloney-Clark, Shane, Zhou, Bin, Chau, Gordon, Robertson, Andreana, Maciejewski, Sonia, Hammond, Holly L, Baracco, Lauren, Logue, James, Frieman, Matthew B, Smith, Gale, Patel, Nita, Glenn, Gregory M, Adams, Mark, Arya, Mark, Athan, Eugene, Berger, Ira, Bradley, Paul, Briskin, Toby, Glover II, Richard, Griffin, Paul, Kim, Joshua, Kitchener, Scott, Klein, Terry, Leah, Amber, Leelasena, Indika, Lemech, Charlotte, Lickliter, Jason, Manning, Mary Beth, Napier-Flood, Fiona, Nugent, Paul, Thackwray, Susan, Turner, Mark

“…Emerging SARS-CoV-2 variants and evidence of waning vaccine efficacy present substantial obstacles towards controlling the COVID-19 pandemic. Booster doses of…”
Get full text

Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques by Conaghan, Philip G, Østergaard, Mikkel, Bowes, Michael A, Wu, Chunying, Fuerst, Thomas, van der Heijde, Désirée, Irazoque-Palazuelos, Fedra, Soto-Raices, Oscar, Hrycaj, Pawel, Xie, Zhiyong, Zhang, Richard, Wyman, Bradley T, Bradley, John D, Soma, Koshika, Wilkinson, Bethanie

“…To explore the effects of tofacitinib-an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA)-with or without methotrexate (MTX), on MRI…”
Get more information

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses by Wilkinson, Bethanie, Patel, Kinjal S., Smith, Katherine, Walker, Robert, Wang, Chengbin, Greene, Ann M., Smith, Gale, Smith, Emily R., Gurwith, Marc, Chen, Robert T.

“…Novavax, a global vaccine company, began evaluating NVX-CoV2373 in human studies in May 2020 and the pivotal placebo-controlled phase 3 studies started in…”
Get full text

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis by Strand, Vibeke, van Vollenhoven, Ronald F, Lee, Eun Bong, Fleischmann, Roy, Zwillich, Samuel H, Gruben, David, Koncz, Tamas, Wilkinson, Bethanie, Wallenstein, Gene

“…To evaluate effects of tofacitinib or adalimumab on patient-reported outcomes (PROs) in patients with moderate to severe RA and inadequate responses to MTX. In…”
Get full text

Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis by Fleischmann, Roy, Strand, Vibeke, Wilkinson, Bethanie, Kwok, Kenneth, Bananis, Eustratios

“…ObjectiveTo compare the relationship between clinical measures and patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) treated with…”
Get full text

Tofacitinib versus Methotrexate in Rheumatoid Arthritis by Sexton, Donal, Yuan, Kai, Chen, Jianxin, Xu, Anlong, Wilkinson, Bethanie, Krishnaswami, Sriram, van Vollenhoven, Ronald F

“…To the Editor: In the article by Lee et al. (June 19 issue), 1 the reported elevation in levels of serum creatinine and low-density lipoprotein (LDL)…”
Get full text

Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6 by Vollenhoven, Ronald F., Lee, Eun Bong, Fallon, Lara, Zwillich, Samuel H., Wilkinson, Bethanie, Chapman, Douglass, DeMasi, Ryan, Keystone, Edward

“…Objective Optimal targeted treatment in rheumatoid arthritis requires early identification of failure to respond. This post hoc analysis explored the…”
Get full text

Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials by Strand, Vibeke, Lee, Eun Bong, Yazici, Yusuf, Dikranian, Ara, Wilkinson, Bethanie, Takiya, Liza, Zang, Chuanbo, Bananis, Eustratios, Bergman, Martin J.

“…Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. We evaluated the relationship between disease activity, according to…”
Get full text

Co‐administration of the JAK inhibitor CP‐690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment by Cohen, Stanley, Zwillich, Samuel H., Chow, Vincent, LaBadie, Robert R., Wilkinson, Bethanie

“…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • CP‐690,550 is a novel JAK inhibitor in development as a therapy for rheumatoid arthritis. • Methotrexate is the…”
Get full text

Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials by Wallenstein, Gene V, Kanik, Keith S, Wilkinson, Bethanie, Cohen, Stanley, Cutolo, Maurizio, Fleischmann, Roy, Genovese, Mark C, Gomez Reino, Juan, Gruben, David, Kremer, Joel, Krishnaswami, Sriram, Lee, Eun Bong, Pascual-Ramos, Virginia, Strand, Vibeke, Zwillich, Samuel H

“…Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we investigated the effects of tofacitinib on…”
Get full text